Recent outbreaks, like the deadly Bundibugyo ebolavirus, are a reminder of how quickly dangerous pathogens can emerge and spread, but they also hint at what is possible when the right capabilities, pa...

CEPI is investing US$3.9 million in three research projects that will turn real-time outbreak data into actionable insights to guide the Bundibugyo ebolavirus response in the DRC and support vaccine t...

The funding will advance clinical testing of Immunoscript's thermostable next-generation RNA vaccine platform.

Over 120 experts working across the vaccine and epidemic preparedness research ecosystem in Indonesia and the region are taking part in the table-top event in Jakarta.

A new outbreak of mpox in Guinea-Bissau, the first recorded in the country, is a stark reminder that the virus remains a global threat. Mpox is not a new disease, but since the virus began spreading m...

The first 100 days of the Bundibugyo outbreak show how far epidemic response has advanced and how far it still has to go. It's painful proof that in a deadly epidemic, even faster than ever is often n...

CEPI-backed studies will analyse blood samples from thousands of people who have already been vaccinated against Zaire ebolavirus, with first results expected within months.

A tragic milestone was reached this month as the Bundibugyo ebolavirus outbreak – the fastest-growing Ebola outbreak on record - continues to escalate, with more than 1,400 deaths now recorded. As the...

No vaccine is currently approved against the virus. The rVSV vaccine candidate could become an important tool for Bundibugyo outbreak control and response.

Throughout 2026, we’re capturing voices of support from across our Coalition, highlighting why continued investment in CEPI is crucial for securing a future against epidemics and pandemic threats.